Target
G protein–coupled receptor family C group 5 member D
3 abstracts
Abstract
Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.Org: Vanderbilt University Medical Center, University Hospital of Salamanca, Helen Diller Family Comprehensive Cancer Center, Princess Margaret Cancer Centre, Levine Cancer Institute/Atrium Health,
Abstract
Efficacy, safety, pharmacokinetic (PK), and pharmacodynamic (PD) support for talquetamab (tal) QW and Q2W dosing in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Analyses from MonumenTAL-1.Org: Janssen Research & Development, Sarah Cannon Research Institute/Tennessee Oncology, City of Hope Comprehensive Cancer Center,
Abstract
Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).Org: Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, AR, Centre Hospitalier Universitaire de Nantes, Nantes, France, University Medical Center of Utrecht, Utrecht, Netherlands, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands, Clínica Universidad de Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain, University Hospital of Salamanca/IBSAL/CIC/CIBERONC, Salamanca, Spain, University Hospital of Würzburg, Würzburg, Germany, University of Michigan, Rogel Cancer Center at the time that the work was performed, Ann Arbor, MI, Janssen Research & Development, Spring House, PA, Janssen Research & Development, Madrid, Spain, Janssen Research & Development, Raritan, NJ, Janssen Research & Development at the time that the work was performed, Raritan, NJ, Mount Sinai School of Medicine, New York, NY,